You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Claims for Patent: 9,387,244


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,387,244
Title:Methods for reducing global chronic inflammation and the presence of melanoma
Abstract: This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided.
Inventor(s): Markovic; Svetomir N. (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research (Roschester, MN)
Application Number:14/051,849
Patent Claims:1. A method for treating a mammal having stage IV melanoma, said method comprising: (a) administering to said mammal an anti-chronic inflammation treatment, (b) detecting, in a blood sample obtained from said mammal, a reduction in IL-4, IL-5, IL-10, and IL-13 level following said step (a), wherein said reduction is indicative of reduced global chronic inflammation, and (c) after detecting said reduced global chronic inflammation, administering to said mammal a cancer treatment agent under conditions wherein the presence of said melanoma is reduced, wherein said cancer treatment agent is paclitaxel, carboplatin, bevacizumab, anti-CTLA-4, a MART-1 cancer vaccine, a gp 100 cancer vaccine, a survivin cancer vaccine, or a tyrosinase cancer vaccine.

2. The method of claim 1, wherein said mammal is a human.

3. The method of claim 1, wherein said anti-chronic inflammation treatment comprises chemotherapy, radiation, an anti-IL-4 agent, an anti-IL-13 agent, or a steroid treatment.

4. The method of claim 1, wherein said cancer treatment agent is a cancer vaccine.

5. The method of claim 1, wherein said cancer vaccine is a Melan-A (MART-1), gp100, or survivin cancer vaccine.

6. The method of claim 1, wherein the period of time between the last administration of said anti-chronic inflammation treatment and the first administration of said cancer treatment agent is between two weeks and six months.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.